Boston Scientific has closed a $4 billion deal to purchase BTG to boost its portfolio of minimally invasive procedures that address cancer and vascular diseases.

The deal will allow Boston Scientific to expand its services to cater to patients with liver and kidney cancers, and to provide technology to treat those with deep vein thrombosis, pulmonary embolism, and superficial venous disease.

Not only this, Boston Scientific’s acquisition of BTG will also take over its specialty pharmaceuticals business which comprises of two segments: one which manufactures acute care antidotes to treat overexposure to certain medicines and toxins, and the other licensing arm that handles the royalties in relation to BTG’s intellectual property and product license agreements.

The acquisition is expected to allow Boston Scientific to boost its coverage across the world, with further growth plans anticipated in the pipeline.

Chairman and CEO of Boston Scientific, Mike Mahoney, said: "The addition of the BTG Interventional Medicine portfolio reinforces our category leadership strategy and enables us to offer best-in-class technologies, unparalleled clinical evidence and a strengthened commercial infrastructure to support physicians treating some of the most challenging diseases impacting patient health around the world. Leveraging the employee talent and clinical and commercial expertise of these two high-performing organisations will generate continued innovation and access so that we may advance patient care in ways that neither company could do alone."

Contact us


Tel: +44 (0)1424 777745

Fax: +44 (0)1424 777746



Kirkham Young Ltd.
The Old Court House
North Trade Road
East Sussex
TN33 0EX